Finance entity
Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention Baozun, the most common co-covered peer. Source depth averages 5 original sources per story, versus 2.5 across the same-window beat baseline.
Last mentioned: Mar 26, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, earnings. Of the tracked stories, 1 of 1 also mention Baozun, the most common co-covered peer. Source depth averages 5 original sources per story, versus 2.5 across the same-window beat baseline. The 6 average consequence score is below the beat benchmark of 6.2 in the same window. We currently track 1 Finance story that mention Mark A. Emalfarb, all published on March 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 40 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Mark A. Emalfarb. Shared-story counts are live from our verified record — not editorial picks.
Small-cap innovators across biotech, semiconductors, and fintech reported pivotal Q4 2025 results, signaling a transition from R&D-heavy phases to commercial scaling. Key players like Precigen and Dyadic reached major product launch milestones, while Paysign and Baozun demonstrated robust operational leverage through specialized market expansion.
Mark A. Emalfarb is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
